Biotech News

Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

Sagimet Biosciences (SGMT)Sagimet BiosciencesEarnings

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regulator, for acne, today reported financial results for the quarter ended September 30, 2026, and provided corporate updates.

Related news

Sagimet Biosciences

Metabolic Pathway Therapeutics Sagimet Biosciences develops fatty acid synthase inhibitors for diseases driven by abnormal lipid production. Denifanstat Denifanstat is an oral FASN inhibitor that reduces de novo lipogenesis and has been studied in both metabolic liver disease and dermatology. Dermatology Focus Sagimet is prioritizing...

Recent company news

Stock data

Close
9.62 USD
Market cap
419.29M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States